Anticancer Palliative Care

Product Details:

• Amifostine is used to decrease the risk of kidney problems caused by treatment with a certain anti-cancer drug (cisplatin). It is also used to help prevent a certain side effect (dry mouth) caused by radiation treatment for head and neck cancer. Amifostine is thought to work by preventing certain chemicals from damaging healthy cells. It may also help repair cells damaged by cisplatin or radiation treatment.

• For Reduction of Cumulative Renal Toxicity with Chemotherapy-
• The recommended starting dose of Amifostine for Injection is 910 mg/m2 administered once daily as a 15-minute i.v. infusion, starting 30 minutes prior to chemotherapy.
• The 15-minute infusion is better tolerated than more extended infusions. Further reductions in infusion times for chemotherapy regimens have not been systematically investigated.
• Patients should be adequately hydrated prior to Amifostine for Injection infusion and kept in a supine position during the infusion. Blood pressure should be monitored every 5 minutes during the infusion, and thereafter as clinically indicated.

• The recommended dose of Amifostine for Injection is 200 mg/m2 administered once daily as a 3-minute i.v. infusion, starting 15-30 minutes prior to standard fraction radiation therapy (1.8-2.0 Gy).

Product Details:

• Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
• Prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.

• Chemotherapy induced Nausea & Vomiting.

• Oral Dose Administrated 24 mg, 30 minutes before the start of single day highly emetogenic chemotherapy.
• Children 150 mcg per kg body weight (6 months to 18 years).
• For prevention of postoperative nausea and vomiting

• Oral Dose 16 mg given as two 8-mg ondansetron tab.
• Children (1 month to 12 years) 100mcg/kg of weight for children weighing 40 kg or less, or 4 mg for children weighing over 40 kg.

Product Details:

• Fluorouracil may be used alone, or in combination for its palliative action in the management of common malignancies particularly cancer of the colon and breast, either as a single agent or in combination with other cytotoxic agents.
• Fluorouracil is indicated in adults.
• Fluorouracil is indicated in the treatment of the following malignancies and disease settings:
• In the treatment of metastatic colorectal cancer
• As adjuvant treatment in colon and rectal cancer
• In the treatment of advanced gastric cancer, pancreatic cancer, oesophageal cancer, metastatic breast cancer,
• As adjuvant treatment in patients with operable primary invasive breast cancer,
• In the treatment of inoperable locally advanced squamous cell carcinoma of the head and neck in previously untreated patients
• In the treatment of locally recurrent or metastatic squamous cell carcinoma of the head and neck

• Fluorouracil injection can be given by intravenous injection or, intravenous or intra-arterial infusion.
• Fluorouracil injection should not be mixed directly, in the same container, with other chemotherapeutic agents or intravenous additives.

• Initial Treatment: This may be in the form of an infusion or an injection, the former usually being preferred because of lesser toxicity.
• Intravenous infusion: 15mg/kg bodyweight but not more than 1g per infusion, diluted in 500ml of 5% glucose or 0.9% NaCl injection and given by intravenous infusion at a rate of 40 drops per minute over 4 hours. Alternatively the daily dose may be infused over 30 60 minutes or may be given as a continuous infusion over 24 hours. The infusion may be repeated daily until there is evidence of toxicity or a total dose of 12 15g has been reached.
• Intravenous Injection: 12mg/kg bodyweight, but not more than the recommended 1g daily dose may be given daily for 3 days and then, if there is no evidence of toxicity, 6mg/kg on alternate days for 3 further doses. An alternative regimen is 15mg/kg as a single intravenous injection once a week throughout the course.
• Intra-arterial Infusion: 5/7.5mg/kg may be given by 24 hour continuous intra-arterial infusion.

Product Details:

• Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
• Prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.

• Chemotherapy - Induced Nausea & Vomiting

• IV Dose 32mg IV or 150 mcg per kg of body weight.
• Children 150 mcg per kg body weight (6 months to 18 years).
• For prevention of postoperative nausea and vomiting

• IV Dose 4 mg IV over a period of thirty sec. to five min. (Given just before anesthesia).
• Children (1 month to 12 years) 100mcg/kg of weight for children weighing 40 kg or less, or 4 mg for children weighing over 40 kg.

Product Details:

• Granisetron is indicated in adults for the prevention and treatment of
• Acute nausea and vomiting associated with chemotherapy and radiotherapy.
• Post-operative nausea and vomiting.
• Granisetron is indicated for the prevention of delayed nausea and vomiting associated with chemotherapy and radiotherapy.
• Granisetron is indicated in children aged 2 years and above for the prevention and treatment of acute nausea and vomiting associated with chemotherapy.

• Chemo- and radiotherapy-induced nausea and vomiting (CINV and RINV)
• Prevention (acute and delayed nausea and vomiting): A dose of 1 - 3 mg (10 - 40 ??g/kg) of Granisetron should be administered either as a slow intravenous injection or as a diluted intravenous infusion 5 minutes prior to the start of chemotherapy or radiotherapy. The solution should be diluted to 5 ml per mg.
• Treatment (acute nausea and vomiting): A dose of 1 - 3 mg (10 - 40 ??g/kg) of Granisetron should be administered either as a slow intravenous injection or as a diluted intravenous infusion and administered over 5 minutes. The solution should be diluted to 5 ml per mg.
• Further maintenance doses of Granisetron may be administered at least 10 minutes apart. The maximum dose to be administered over 24 hours should not exceed 9 mg.
• Combination with adrenocortical steroid: The efficacy of parenteral granisetron may be enhanced by an additional intravenous dose of an adrenocortical steroid e.g. by 8 - 20 mg dexamethasone administered before the start of the cytostatic therapy or by 250 mg methyl-prednisolone administered prior to the start and shortly after the end of the chemotherapy.
• Paediatric population:The safety and efficacy of granisetron in children aged 2 years and above has been well established for the prevention and treatment (control) of acute nausea and vomiting associated with chemotherapy. A dose of 10 - 40 ??g/kg body weight (up to 3 mg) should be administered as an IV infusion, diluted in 10 - 30 ml infusion fluid and administered over 5 minutes prior to the start of chemotherapy. One additional dose may be administered within a 24 hour-period if required. This additional dose should not be administered until at least 10 minutes after the initial infusion.
• Post-operative nausea and vomiting (PONV): A dose of 1 mg (10??g/kg) of Granisetron should be administered by slow intravenous injection. The maximum dose of Granisetron to be administered over 24 hours should not exceed 3 mg.